Impact Factor 4.716 | CiteScore 4.71
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.02393

Induction of tolerance and immunity by dendritic cells: mechanisms and clinical applications

 Jitka Fucikova1, 2*,  Lenka Palová Jelínková1, 2, Jirina Bartunkova1, 2 and  Radek Spisek1, 2
  • 1SOTIO a.s., Czechia
  • 2Department of Immunology, 2nd Faculty of Medicine, University Hospital in Motol, Czechia

Dendritic cells (DCs) are key regulators of immune responses that operate at the interface between innate and adaptive immunity, and defects in DC functions contribute to the pathogenesis of a variety of disorders. For instance, cancer evolves in the context of limited DC activity, and some autoimmune diseases are initiated by DC-dependent antigen presentation. Thus, correcting aberrant DC functions stands out as a promising therapeutic paradigm for a variety of diseases, as demonstrated by an abundant preclinical and clinical literature accumulating over the past two decades. However, the therapeutic potential of DC-targeting approaches remains to be fully exploited in the clinic. Here, we discuss the unique features of DCs that underlie the high therapeutic potential of DC-targeting strategies and critically analyze the obstacles that have prevented the full realization of this promising paradigm.

Keywords: Dendritic Cells, Immunotherapy, Cancer, Autoimmune disorder, Vaccine preparation

Received: 18 Jul 2019; Accepted: 24 Sep 2019.

Copyright: © 2019 Fucikova, Palová Jelínková, Bartunkova and Spisek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mx. Jitka Fucikova, SOTIO a.s., Prague, 170 00, Prague, Czechia, fucikova@sotio.com